Virax Biolabs Group Ltd
VRAX0.861USD
+0.016+1.83%
시장 운영 시간 （ET）시세는 15분 지연됩니다
3.74M시가총액
--P/E TTM
자세한 내용은 Virax Biolabs Group Ltd 회사
Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The Company is engaged in developing a T-Cell Test technologies with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against global viral threats. Its product portfolio includes ViraxClear and Virax Immune. ViraxClear offers a range of accurate diagnostic testing kits and machines. Virax Immune is a new Covid-19 test seeking detection of T-Cell immune responses to the SARS-Cov-2 virus. Its T-Cell testing is effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Monkeypox, Hepatitis B, Malaria, Herpes and Human Papillomavirus.
회사 정보
종목 코드 VRAX
회사 이름Virax Biolabs Group Ltd
상장일Jul 14, 2022
CEOMr. James Foster
직원 수19
유형Ordinary Share
회계 연도 종료Jul 14
주소Biocity Glasgow
도시LONDON
증권 거래소NASDAQ Capital Market Consolidated
국가United Kingdom
우편 번호ML1 5UH
전화4402077887414
웹사이트https://www.viraxbiolabs.com
종목 코드 VRAX
상장일Jul 14, 2022
CEOMr. James Foster
회사 임원
이름
이름/직위
직위
주식 보유
변동
Mr. James Foster
Mr. James Foster
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
368.57K
+27.98%
Mr. Evan Norton
Mr. Evan Norton
Independent Director
Independent Director
15.33K
--
Dr. Iain Miller
Dr. Iain Miller
Independent Director
Independent Director
--
--
Mr. Nelson M. Haight
Mr. Nelson M. Haight
Independent Director
Independent Director
--
--
Mr. Jason D. Davis
Mr. Jason D. Davis
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Nigel Mccracken, Ph.D.
Dr. Nigel Mccracken, Ph.D.
Chief Operating Officer, Director
Chief Operating Officer, Director
--
--
이름
이름/직위
직위
주식 보유
변동
Mr. James Foster
Mr. James Foster
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
368.57K
+27.98%
Mr. Evan Norton
Mr. Evan Norton
Independent Director
Independent Director
15.33K
--
Dr. Iain Miller
Dr. Iain Miller
Independent Director
Independent Director
--
--
Mr. Nelson M. Haight
Mr. Nelson M. Haight
Independent Director
Independent Director
--
--
Mr. Jason D. Davis
Mr. Jason D. Davis
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Nigel Mccracken, Ph.D.
Dr. Nigel Mccracken, Ph.D.
Chief Operating Officer, Director
Chief Operating Officer, Director
--
--
수익 분석
데이터 없음
데이터 없음
사업별
지역별
데이터 없음
주식 보유 통계
마지막 업데이트: Sun, Jul 6
마지막 업데이트: Sun, Jul 6
주주
주주 유형
주주
주주
비율
Foster (James)
8.49%
Armistice Capital LLC
5.25%
Mccracken (Nigel Ph.D.)
0.54%
UBS Financial Services, Inc.
0.52%
Norton (Evan)
0.35%
Other
84.85%
주주
주주
비율
Foster (James)
8.49%
Armistice Capital LLC
5.25%
Mccracken (Nigel Ph.D.)
0.54%
UBS Financial Services, Inc.
0.52%
Norton (Evan)
0.35%
Other
84.85%
주주 유형
주주
비율
Individual Investor
6.63%
Hedge Fund
5.88%
Investment Advisor
0.83%
Other
86.66%
기관 주식 보유
마지막 업데이트: Tue, Jul 1
마지막 업데이트: Tue, Jul 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q2
26
729.04K
16.79%
+148.45K
2025Q1
23
579.67K
13.35%
-10.90K
2024Q4
24
579.58K
13.35%
-22.54K
2024Q3
22
734.94K
16.93%
+329.85K
2024Q2
22
359.31K
9.40%
-99.69K
2024Q1
20
305.99K
7.33%
-151.07K
2023Q4
20
422.04K
26.02%
+96.63K
2023Q3
24
636.78K
40.92%
-179.86K
2023Q2
22
639.17K
41.06%
-174.53K
2023Q1
21
797.76K
51.31%
+134.82K
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Foster (James)
368.57K
8.49%
+80.58K
+27.98%
Mar 31, 2025
Armistice Capital LLC
228.04K
5.25%
+228.04K
--
Sep 30, 2024
Mccracken (Nigel Ph.D.)
23.33K
0.54%
+23.33K
--
Mar 31, 2025
UBS Financial Services, Inc.
22.43K
0.52%
-15.49K
-40.85%
Mar 31, 2025
Norton (Evan)
15.33K
0.35%
+15.33K
--
Mar 31, 2025
Erez (Yair)
15.33K
0.35%
+15.33K
--
Mar 31, 2025
Haight (Nelson)
15.33K
0.35%
+15.33K
--
Mar 31, 2025
Two Sigma Investments, LP
13.63K
0.31%
+13.63K
--
Mar 31, 2025
Citadel Advisors LLC
13.54K
0.31%
+13.54K
--
Mar 31, 2025
HRT Financial LP
13.51K
0.31%
+13.51K
--
Mar 31, 2025
더 보기
관련 ETF
이름
비율
데이터 없음
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
Dec 14, 2023
Merger
10<1
Dec 14, 2023
Merger
10<1
Dec 14, 2023
Merger
10<1
Dec 14, 2023
Merger
10<1
날짜
유형
비율
Dec 14, 2023
Merger
10<1
Dec 14, 2023
Merger
10<1
Dec 14, 2023
Merger
10<1
Dec 14, 2023
Merger
10<1
